Trials / Completed
CompletedNCT00257608
A Study Comparing Bevacizumab Therapy With or Without Erlotinib for First-Line Treatment of Non-Small Cell Lung Cancer (ATLAS)
A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 1,145 (actual)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bevacizumab | Intravenous repeating dose |
| DRUG | placebo | Oral repeating dose |
| DRUG | erlotinib HCl | Oral repeating dose |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2014-11-01
- Completion
- 2014-11-01
- First posted
- 2005-11-23
- Last updated
- 2016-04-18
- Results posted
- 2016-03-15
Locations
247 sites across 17 countries: United States, Argentina, Australia, Belgium, Brazil, Bulgaria, Hong Kong, Israel, Italy, Mexico, Philippines, Romania, Singapore, Spain, Taiwan, Thailand, United Kingdom
Source: ClinicalTrials.gov record NCT00257608. Inclusion in this directory is not an endorsement.